TrialJournal for immunotherapy of cancer2021

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.

Walter J Storkus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.